Bin Abdulhak Aref A, Robinson Jennifer G
Division of Cardiovascular Medicine, Department of Internal Medicine, University of Iowa Carver College of Medicine, 200 Hawkins Drive, Iowa City, IA 52242, USA; Department of Epidemiology, University of Iowa, College of Public Health, 200 Hawkins Drive, Iowa City, IA 52242, USA; Prevention Intervention Center, University of Iowa, College of Public Health, 200 Hawkins Drive, Iowa City, IA 52242, USA.
Division of Cardiovascular Medicine, Department of Internal Medicine, University of Iowa Carver College of Medicine, 200 Hawkins Drive, Iowa City, IA 52242, USA; Prevention Intervention Center, University of Iowa, College of Public Health, 200 Hawkins Drive, Iowa City, IA 52242, USA; Department of Epidemiology, University of Iowa, College of Public Health, 145 North Riverside Drive, S455 CPHB, Iowa City, IA 52242, USA; Department of Medicine, University of Iowa Hospitals and Clinics, 200 Hawkins Drive, Iowa City, IA 52242, USA.
Cardiol Clin. 2018 May;36(2):221-223. doi: 10.1016/j.ccl.2017.12.003.
Statins are essential medications in the management of patients with clinical atherosclerotic cardiovascular disease, and have been supported by numerous clinical trials. Emerging evidence suggests that adding ezetimibe to statin therapy is associated with a net benefit and improved hard clinical outcomes, particularly in patients with significantly elevated atherosclerotic cardiovascular disease risk and elevated low-density lipoprotein cholesterol levels.
他汀类药物是临床动脉粥样硬化性心血管疾病患者管理中的重要药物，并得到了众多临床试验的支持。新出现的证据表明，在他汀类药物治疗中加用依泽替米贝具有净获益，并能改善临床硬终点结局，特别是在动脉粥样硬化性心血管疾病风险显著升高且低密度脂蛋白胆固醇水平升高的患者中。
